FIELD: biotechnology.
SUBSTANCE: invention relates to the polypeptides that bind to OX40, and can be used in medicine for cancer treatment. The following is proposed: a polypeptide that binds to OX40, containing at least one VHH domain that binds to OX40 and contains the amino acid sequence of the following SEQ ID NO: 9 and the Fc domain.
EFFECT: invention provides for the production of a single-domain antibody (sdAb) which in the bivalent format has reduced non-specific binding to non-transfected HEK293 cells compared to 1D10v1-Fc, and in the hexavalent format, in addition to reduced non-specific binding compared to the hexavalent 3x1D10v1-Fc, is also a more effective agonist OX40 compared to bivalent and tetravalent variants.
60 cl, 15 dwg, 3 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-OX40 ANTIBODIES AND THEIR APPLICATION | 2017 |
|
RU2753493C2 |
| BISPECIFIC BINDING PROTEINS AND APPLICATION WAYS THEREOF | 2017 |
|
RU2766199C2 |
| BISPECIFIC 2+1 ANTIBODIES | 2018 |
|
RU2797305C2 |
| ANTIBODY MOLECULES THAT BIND CD137 AND OX40 | 2019 |
|
RU2817602C2 |
| ANTI-TIGIT ANTIBODIES AND METHODS OF USING | 2016 |
|
RU2732591C2 |
| ANTIBODIES AGAINST OX40 AND THEIR USE | 2017 |
|
RU2783314C2 |
| IMMUNOCYTOKINES AND THEIR USE | 2021 |
|
RU2818371C1 |
| BISPECIFIC ANTIBODIES SPECIFIC RELATIVELY TO COSTIMULATORY TNF-RECEPTOR | 2016 |
|
RU2761115C1 |
| POLYVALENT AND POLYSPECIFIC OX40-BINDING FUSED PROTEINS | 2017 |
|
RU2773052C2 |
| ANTI-TIGIT ANTIBODIES AND METHODS OF USE | 2016 |
|
RU2817838C2 |
